CLL: Applying Diagnostic Markers in Clinical Practice and Incorporating Updated Guidelines into Treatment Plans

As a healthcare professional, you can enhance your decision making as you learn from leading experts in Chronic Lymphocytic Leukemia (CLL).  

Join our expert editorial panel as they offer a curated collection of patient case studies and key take-home messages on Chronic Lymphocytic Leukemia (CLL). Gain valuable perspectives on the latest advancements, challenges, and best practices in the diagnosis and management of CLL. 

Watch now to advance your practice and improve the lives of patients with CLL.  

Target Audience

Healthcare Professionals

This activity is supported by an educational grant from Eli Lilly.

Course summary

Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
Course opens: 
05/02/2025
Course expires: 
05/01/2028
Cost:
$0.00
Rating: 
0
Dr. Martin Šimkovič, Ph.D

Dr. Martin Šimkovič, Ph.D

Lead, Chronic Lymphocytic Leukemia (CLL) treatment group, IV. Internal Hematology Clinic, University Hospital Hradec Králové

Dr. Martin Šimkovič, Ph.D discloses the following: There is nothing to disclose

Dr. Romain Guieze

Dr. Romain Guieze

Professor of Hematology, CHU Clermont-Ferrand, University Clermont Auvergne, France

Dr. Othman Al-Sawaf

Dr. Othman Al-Sawaf

Haematologist and Medical Oncologist, University Hospital Cologne, Cologne, Germany
Principal Investigator, German CLL Study Group (GCLLSG)

Dr. Othman Al-Sawaf discloses the following: Speaker/presentation fees from Roche, Janssen, Gilead, AbbVie, Lilly, AstraZeneca, Adaptive, and BeiGene; research grants from BeiGene, Roche, Janssen, and AbbVie; and consulting fees from Roche, Janssen, Gilead, AbbVie, Lilly, AstraZeneca, Ascentage, BeiGene, and Genmab.

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.